Get the Stockscreener App
1.03
0.00%
0.00
After Hours:
1.02
-0.01
-0.97%
Clearmind Medicine Inc stock is traded at $1.03, with a volume of 50,684.
It is up +0.00% in the last 24 hours and up +14.46% over the past month.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$1.03
Open:
$1.03
24h Volume:
50,684
Relative Volume:
0.06
Market Cap:
$4.39M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.0241
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
+3.00%
1M Performance:
+14.46%
6M Performance:
-29.93%
1Y Performance:
-37.58%
1-Day Range:
$1.0166
$1.08
1-Week Range:
$1.00
$1.25
52-Week Range:
$0.80
$2.18
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.03 | 5.54M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind Medicine Inc. Stock Analysis and ForecastRapidly expanding wealth - PrintWeekIndia
Is Clearmind Medicine Inc. a good long term investmentHigh-performance investment picks - PrintWeekIndia
Why TRUMP(maga) Will ExplodeMarket Ready Callouts - Newser
What drives Clearmind Medicine Inc. stock priceExceptional trading results - Autocar Professional
What analysts say about Clearmind Medicine Inc. stockPowerful growth strategies - Autocar Professional
Clearmind Medicine Inc Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder - MarketScreener
Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder - The Manila Times
Clearmind advances AUD treatment with new trial site in Tel Aviv - Investing.com
Clearmind Medicine Inc. Announces Successful Site Initiation for Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center - Nasdaq
Clearmind Medicine Surges 18.99%: What's Fueling This Volatile Biotech Rally? - AInvest
How Clearmind Medicine Inc. stock reacts to Fed policy changesFree Access to Community with 300% Return - beatles.ru
What makes Clearmind Medicine Inc. stock price move sharplySmart Money Trade Setups - beatles.ru
Clearmind Expands its Clinical Trial for Alcohol Use, New Site Activated and Additional Participant Enrolled - MarketScreener
How Clearmind Medicine Inc. stock performs during market volatilityFree High-Accuracy Stock Picks - Newser
Why Clearmind Medicine Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser
Clearmind Expands Its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled - MarketScreener
Clearmind expands phase I/IIa trial for alcohol use disorder treatment By Investing.com - Investing.com South Africa
Clearmind expands phase I/IIa trial for alcohol use disorder treatment - Investing.com India
Clearmind Medicine Inc. Expands Phase I/IIa Clinical Trial for CMND-100 to Johns Hopkins University to Address Alcohol Use Disorder - Nasdaq
Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled - The Manila Times
Clearmind Medicine (NASDAQ:CMND) Stock Price Up 4.5% – Here’s Why - Defense World
Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck - Yahoo Finance
Clearmind Medicine Soars 32.89% on Clinical Trial Approval - AInvest
CMND’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Clearmind Gains IRB Approval At TASMC For Alcohol Use Disorder Drug Trial - Nasdaq
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):